Gouws Capital LLC Trims Stock Position in Zoetis Inc. $ZTS

Gouws Capital LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 30.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,955 shares of the company’s stock after selling 5,346 shares during the quarter. Zoetis accounts for about 1.0% of Gouws Capital LLC’s investment portfolio, making the stock its 23rd largest position. Gouws Capital LLC’s holdings in Zoetis were worth $1,749,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Scott & Selber Inc. boosted its stake in shares of Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after acquiring an additional 67 shares during the last quarter. North Star Asset Management Inc. raised its holdings in Zoetis by 4.9% in the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after purchasing an additional 67 shares during the period. Moment Partners LLC lifted its position in Zoetis by 3.2% during the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares in the last quarter. CVA Family Office LLC lifted its position in Zoetis by 6.7% during the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares in the last quarter. Finally, Bank of Nova Scotia Trust Co. grew its holdings in Zoetis by 4.6% during the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock valued at $264,000 after purchasing an additional 74 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZTS. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday. Finally, Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research note on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $124.35 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The firm has a fifty day moving average price of $123.51 and a 200 day moving average price of $138.66. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The firm has a market cap of $54.80 billion, a price-to-earnings ratio of 20.93, a P/E/G ratio of 2.17 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.69%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.